CT SB00371

Allows patients with terminal illnesses (expected to result in death or permanent unconsciousness within one year) to access investigational drugs, biological products, or devices that have completed phase one FDA testing but lack final FDA approval.

Requires eligible patients to have considered all approved treatments, been unable to participate in a nearby clinical trial (within 100 miles or one week of application), received physician recommendation, and provided written informed consent detailing risks, potential outcomes, and financial liability.

Prohibits the Connecticut Medical Examining Board or Department of Public Health from disciplining physicians who recommend investigational treatments consistent with medical standards of care.

Allows manufacturers to provide investigational drugs to eligible patients either free of charge or by requiring patients to pay manufacturing costs, with liability protection for manufacturers.

Permits health carriers to cover investigational treatments for eligible patients but allows coverage denial for up to six months after treatment ends, with exceptions for preexisting conditions and benefits commenced before treatment began.